ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag academia genetics genomics

Tagged for Cleansing
Michele Pagano | Jun 1, 2009 | 10+ min read
Tagged for Cleansing Not just the cell's trash and recycling center, the ubiquitin system controls complex cellular pathways with elegant simplicity and precision. By Michele Pagano have always gravitated toward order. I may even take it a bit too far according to friends who liken my office to a museum. However, I like to think it not a compulsion, but a Feng Shui approach to life. With this need for order, I may have been better suited to
Synthego Launches High Throughput Induced Pluripotent Stem Cell Genome Engineering
Synthego | Oct 29, 2019 | 2 min read
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Notebook
Paul Smaglik | Nov 21, 1999 | 6 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria UCSD - Salk Program in Molecular Medicine HEART FAILURE RESCUE: A cross section of a mouse genetically engineered to develop heart failure (left) shows enlarged heart chambers and thin walls that are typical of the condition. A cross section from the same strain of mouse, but with the phospholamban gene (PLB) also missing, appears normal. PIVOTAL PUMP A biochemical calcium pump and the gene that con
Top 10 Innovations 2014
The Scientist | Dec 1, 2014 | 10+ min read
The list of the year’s best new products contains both perennial winners and innovative newcomers.
My Mighty Mouse
Megan Scudellari | Apr 1, 2015 | 10+ min read
Personal drug regimens based on xenograft mice harboring a single patient’s tumor still need to prove their true utility in medicine.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Mail
The Scientist Staff | Dec 1, 2007 | 6 min read
To frame, or not to frame? Re: "The future of public engagement,"1 the first thing scientists need to do is abandon all talk of tentativeness, paradigms, and social construct when talking to the public about science. This model of science is appropriate in certain circles, but I see not a shred of evidence that it has improved public scientific literacy, and [I see] a great deal of evidence that it has been used by charlatans to dismiss scientific findings or push bogus alternativ

Run a Search

ADVERTISEMENT